β¨ Medicines Approval Notices
30 JUNE NEW ZEALAND GAZETTE 2161
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Zinc (as Zinc Sulphate heptahydrate) 1.0 mg, Copper (as Cupric Sulphate pentahydrate) 0.4 mg, Manganese (as Manganese Sulphate monohydrate) 0.1 mg, Chromium (as Chromic Chloride hexahydrate) 4 mcg, Selenium (as Selenious acid) 20 mcg, Iodide (as Sodium Iodide) 25 mcg, Molybdenum (as Ammonium molybdate tetrahydrate) 25 mcg per ml in 10 ml | Solution for infusion | Lyphomed Inc., Melrose Park, Illinois, United States of America | MTE-7 |
| Polyethylene glycol 4000 5.91% w/v, anhydrous sodium sulphate 0.57% w/v | Powder for reconstitution (oral) | Rice Steele & Company Limited, Tallaght, Dublin, Ireland | Colocler |
| Papaveretum 20 mg in 1 ml | Solution for injection (ampoule) | Astra Pharmaceuticals Pty Limited, North Ryde, New South Wales, Australia | Papaveretum Injection |
| Isoflurane 100% | Volatile liquid for inhalation | Rhone-Poulenc Chemicals Limited, Avonmouth, Bristol, England | Isoflurane Inhalation Anaesthetic |
| Capcipotriol hydrate 50 mcg per g in 30 gram and 100 gram | Cream | Leo Laboratories Limited, Dublin, Ireland | Daivonex |
| Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 133 ml | Enema | C B Fleet & Co Inc., Lynchburg, Virginia, United States of America | Fleet Enema |
| Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 66.6 ml | Enema | C B Fleet & Co Inc., Lynchburg, Virginia, United States of America | Fleet Enema for Children |
| Teicoplanin 100 mg, 200 mg, 400 mg | Freeze dried powder for reconstitution for IV or IM injection | Gruppo Lepetit S.p.A., Anagni (Frosinone), Italy | Targocid Injection |
| Nabumetone 500 mg | Tablet | Beecham Pharmaceuticals, Crawley, Sussex, England | Relifex |
| Interferon gamma-lb 100 mcg in 0.5 ml | Solution for injection | Genentech Inc., South San Francisco, California, United States of America | Imukin |
Dated this 27th day of June 1994.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
go4868
Consent to the Distribution of Changed Medicines
Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Moclobemide 100 mg, 150 mg, 300 mg | Tablets | F Hoffmann-La Roche Limited, Basle, Switzerland | Aurorix |
| Itraconazole 100 mg | Capsule | Janssen Pharmaceutica n.v., Belgium | Sporanox |
| Foscarnet trisodium hexahydrate 24 mg/ml in 250 ml and 500 ml | Intravenous solution for infusion | Astra Pharmaceuticals Production AB., Sodertalje, Sweden and Netherlands Produktielaboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen B.V., Emmer-Compascuum, The Netherlands | Foscavir |
| Cefpodoxime proxetil 52.18 mg equivalent to 40 mg/5 ml when reconstituted with water | Granules for suspension (oral) | Usiphar Production Unit, Compeigne, France | Orelox |
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1994, No 65
NZLII —
NZ Gazette 1994, No 65
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare27 June 1994
Medicines, Distribution, Consent, Schedule
- C. Lovelace, Director-General of Health
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social WelfareMedicines, Distribution, Consent, Changes, Schedule